Board change

May 23, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Company’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that the Board of Directors has decided to appoint its Non-Executive Director Mr. Walter van Pottelberge as Chairman of the Board as of today. Mr. Van Pottelberge will replace Mr. Johan Goossens, who will remain a NonExecutive Director.

AGM resolutions

May 15, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, announces that all proposed resolutions at today’s AGM were passed, except for the proposal to cancel the shares currently held in treasury.

read more

Director shareholding – Block-trades

May 10, 2013 Group News

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that via a block-trade Mr Johan Goossens, Chairman, sold 900,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) to Salveo Holding SA on 7 May 2013 and that at the same day Mr Marc Waeterschoot, co-founder and former Board Member of Cryo-Save, via a block-trade sold 1,460,000 Ordinary Shares to Salveo Holding SA, both at a price of €1.70. Salveo Holding SA has not contacted management of Cryo-Save about its intentions as a major shareholder.

read more

Cryo-Save facilitates the first transplantation in Spain to treat blackfan-diamond anaemia thanks to the cost-free donation program

April 29, 2013 Group News

A 4-year-old boy was treated for Blackfan-Diamond anaemia (BDA) with a stem cell transplant from his sister’s umbilical cord blood. The transplant was performed on April 25 at the Hospital del Niño Jesús in Madrid, one of the most important paediatric hospitals in Spain. It is the first transplant performed in this country to treat BDA with a cryo-preserved sample from a family bank, in this case, the leading Family Stem Cell Bank in Spain, Crio-Cord, a subsidiary of the Cryo-Save Group. This treatment was provided thanks to the Cryo-Save Cost Free Donation Program, which provides free storage of the umbilical cord blood and cord tissue stem cells for families who have a family member diagnosed with a disease treatable with stem cells.

read more

Director shareholding

April 11, 2013 Group News
Tags

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that Mr Arnoud van Tulder, Chief Executive Officer, purchased 4,752 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price of €1.24 on Wednesday 10 April 2013.

read more

Director shareholding

April 9, 2013 Group News
Tags

Cryo-Save Group N.V. (Euronext: CRYO, ‘Cryo-Save’, or ‘the Group’), the leading international stem cell storage company and the largest family stem cell bank in Europe, has been informed that Mr Johan Goossens, Chairman, purchased 100,000 ordinary shares of Euro 0.10 (‘Ordinary Shares’) at a price range between €1.19 and €1.24 on Friday 5 April and on Monday 8 April 2013.

read more

New freezing procedure increases availability of cord blood stem cell transplants for patients

February 7, 2013 Group News

A large enough number of stem cells are needed to ensure the success of a cord blood transplant. However, the quantity of stem cells isolated from umbilical cord blood is not always sufficient to meet that requirement. Researchers from the Etablissement Français du Sang, Aquitaine-Limousin (France) have established a method to multiply cord blood stem cells to required quantity levels. In the current study Dr. Ivanovic and co-workers (Etablissement Français du Sang Aquitaine-Limousin) and a team of Cryo-Save researchers have demonstrated that these cultured stem cells can be frozen and thawed without negatively affecting the quality of the stem cells. An important step towards successful stem cell transplants in patients for whom too few stem cells are available.

read more